NCT06690385 DEPRECAP: Lung Cancer Screening Programme by LDCT for Patients With COPD or Emphysema.
| NCT ID | NCT06690385 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz |
| Condition | Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,998 participants |
| Start Date | 2014-01-14 |
| Primary Completion | 2024-11-13 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,998 participants in total. It began in 2014-01-14 with a primary completion date of 2024-11-13.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The DEPRECAP (Early detection of lung cancer) study is an ongoing, prospective, longitudinal, multicenter lung cancer screening program that recruited individuals with COPD or emphysema from the pulmonary clinics of Fundación Jiménez Díaz University Hospital and Villalba General Hospital, in Madrid, Spain. The aim of this observational study is to determine the scientific evidence needed to study the benefit and potential effects of lung cancer screening in this group of patients and to determine the long-term effects of the intervention in reducing the high mortality rates associated with late-stage lung cancer diagnosis in a very high-risk population, to address under-diagnosis of COPD and to promote smoking cessation. This leads to the creation of a registry with clinical, radiological, functional data and biological samples for future studies in this cohort of patients to provide the scientific evidence needed to study the benefit and potential effects of screening for lung cancer and other tobacco-related pathologies diagnosed by Low-dose CT (LDCT)
Eligibility Criteria
Inclusion Criteria: * Current or former smokers (\>15 years of abstinence) with a cumulative smoking exposure of \> 30 pack-years * Diagnosis of COPD according to the GOLD guidelines and/or emphysema identified by LDCT and/or a carbon monoxide diffusing capacity (DLCO) lower than 80% of predicted (as per the Global Lung Function Initiative (GLI) equations) Exclusion Criteria: * Individuals with a recent history of cancer (except non-melanoma skin cancer or carcinoma in situ) as well as those with other medical conditions that posed a significant risk of death were excluded from the study.
Contact & Investigator
Carolina Gotera, MD
PRINCIPAL INVESTIGATOR
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Frequently Asked Questions
Who can join the NCT06690385 clinical trial?
This trial is open to participants of all sexes, aged 55 Years or older, up to 75 Years, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06690385 currently recruiting?
Yes, NCT06690385 is actively recruiting participants. Contact the research team at carolina.gotera@fjd.es for enrollment information.
Where is the NCT06690385 trial being conducted?
This trial is being conducted at Madrid, Spain, Madrid, Spain.
Who is sponsoring the NCT06690385 clinical trial?
NCT06690385 is sponsored by Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz. The principal investigator is Carolina Gotera, MD at Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz. The trial plans to enroll 1,998 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.